| 000 | 01820cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030921.0 | ||
| 008 | 131230s2013 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.12.04.Ph.D.2013.Ab.E | ||
| 100 | 0 | _aAbdo Abdo Abdellah Mohamed Elfiky | |
| 245 | 1 | 0 |
_aExploring the effect of conformational variability on the biophysical identity of HCV NS5B polymerase / _cAbdo Abdo Abdellah Mohamed Elfiky ; Supervised Wael M. Elshemey , Wissam A. Gawad , Omar S. Desoky |
| 246 | 1 | 5 | _aإستكشاف تأثير التغير البنائى على الشخصية البيوفيزيائية لبوليماريز فيروس سى الكبدى الوبائى |
| 260 |
_aCairo : _bAbdo Abdo Abdellah Mohamed Elfiky , _c2013 |
||
| 300 |
_a153 Leaves : _bcharts ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Science - Department of Biophysics | ||
| 520 | _aPS{u2160}-7977, IDX-{u2160}84 and R7{u2160}28 are hepatitis C virus (HCV) non-structural 5b (NS5B) RNA dependent RNA polymerase (RdRp) nucleotide inhibitors (NIs) that are currently in phase {u2161} ({u2160}DX-{u2160}84 and R7128) and {u2162} (PS{u2160}-7977) clinical trials. The activated form of these Direct Acting aAntiviral (DAA) drugs acts on NS5B RdRp through a coordination bond with the two Mg+² present at the active site of the polymerase | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aHCV | |
| 653 | 4 | _aMolecular | |
| 653 | 4 | _aNS5B | |
| 700 | 0 |
_aOmar S. Desoky , _eSupervisor |
|
| 700 | 0 |
_aWael M. Elshemey , _eSupervisor |
|
| 700 | 0 |
_aWissam A. Gawad , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c44651 _d44651 |
||